Hai-tao Zhao

71 Xinmin St
Changchun, 130021, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 39 publications

Personality, social behavior, and the maintenance of cohesion in a multilevel-society primate ( Rhinopithecus roxellana).

Personality, social behavior, and the maintenance of cohesion in a multilevel-society primate ( Rhinopithecus roxellana).

Journal: Zoological research

Published: March 12, 2026

Optimal duration of adjuvant targeted-immunotherapy in patients with initially unresectable hepatocellular carcinoma with portal vein tumor thrombus following successful conversion therapy.

Optimal duration of adjuvant targeted-immunotherapy in patients with initially unresectable hepatocellular carcinoma with portal vein tumor thrombus following successful conversion therapy.

Journal: The oncologist

Published: December 01, 2025

Efficacy and safety of transcatheter arterial chemoembolization combined with microwave ablation for hepatic hemangiomas (> 5 cm).

Efficacy and safety of transcatheter arterial chemoembolization combined with microwave ablation for hepatic hemangiomas (> 5 cm).

Journal: World journal of gastroenterology

Published: April 29, 2025

Role of extracellular vesicle-associated proteins in the progression, diagnosis, and treatment of hepatocellular carcinoma.

Role of extracellular vesicle-associated proteins in the progression, diagnosis, and treatment of hepatocellular carcinoma.

Journal: Cell & bioscience

Published: May 17, 2024

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study.

Journal: EClinicalMedicine

Published: January 10, 2024

Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis.

Worldwide research trends on tumor burden and immunotherapy: a bibliometric analysis.

Journal: International journal of surgery (London, England)

Published: October 27, 2023

Development and validation of web-based nomograms for predicting survival status in patients with intrahepatic cholangiocarcinoma depending on the surgical status: a SEER database analysis.

Development and validation of web-based nomograms for predicting survival status in patients with intrahepatic cholangiocarcinoma depending on the surgical status: a SEER database analysis.

Journal: Scientific reports

Published: September 12, 2023

Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study.

Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study.

Journal: European journal of medical research

Published: March 18, 2023

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study.

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study.

Journal: BMC cancer

Published: January 10, 2023

Letter to the editor: Cautious interpretation of the compensation of insulin-mTORC1 activation to promote liver regeneration in the absence of hepatocyte β-catenin.

Letter to the editor: Cautious interpretation of the compensation of insulin-mTORC1 activation to promote liver regeneration in the absence of hepatocyte β-catenin.

Journal: Hepatology (Baltimore, Md.)

Published: July 25, 2022

Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study.

Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study.

Journal: Liver cancer

Published: June 16, 2022

Novel cellular therapies for hepatobiliary malignancies.

Novel cellular therapies for hepatobiliary malignancies.

Journal: Hepatobiliary & pancreatic diseases international : HBPD INT

Published: June 01, 2022

Showing 1-12 of 39

Last Updated: 09/26/2026